Incyte wins EU approval for Povofortay in hidradenitis suppurativa
FROM THE WIRE · SEEKINGALPHA.COM
[Approved Document Stamp 3D Render Illustration] * The European Commission has approved Povofortay (povorcitinib), a once-daily pill developed by Incyte (INCY [https://seekingalpha.com/symbol/INCY]) as a treatment for a chronic inflammatory skin disorder known as hidradenitis…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe EU approval opens a new market for Incyte, with potential impact on the drug's future revenue.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The European Commission approved Povofortay, a once-daily pill developed by Incyte.
- 02The drug is indicated for adults with moderate to severe hidradenitis suppurativa.
- 03The approval is based on the pivotal STOP-HS1 and STOP-HS2 trials, which reached their primary endpoints.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets